Serum - Protection from birth onwards
For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory.
SARS-CoV-2 rS Protein (COVID-19) recombinant spike protein Nanoparticle Vaccine
One dose (0.5 ml) contains 5 micrograms of SARS-CoV-2 spike protein* and is adjuvanted with Matrix-M1.
Adjuvanted Matrix-M1 containing per 0.5 ml dose: Fraction-A(42.5 micrograms) and Fraction-C (7.5 micrograms) of Quillaja saponaria Molina extract.
*SARS-CoV-2 recombinant spike protein is produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from Sf9 cells of the Spodoptera frugiperda species.
For the full list of excipients, see section 6.1.
Both COVOVAX™ (manufactured by Serum Institute of India Pvt Ltd) and Nuvaxovid (manufactured by Novavax) are SARS-CoV-2 rS Protein (COVID-19) Nanoparticle Vaccines.